New cephalosporins for the treatment of pneumonia in internal medicine wards.

New cephalosporins for the treatment of pneumonia in internal medicine wards. J Thorac Dis. 2020 Jul;12(7):3747-3763 Authors: Lupia T, Corcione S, Mornese Pinna S, De Rosa FG Abstract The burden of hospital admission for pneumonia in internal medicine wards may not be underestimated; otherwise, cases of pneumonia are a frequent indication for antimicrobial prescriptions. Community- and hospital-acquired pneumonia are characterized by high healthcare costs, morbidity and non-negligible rates of fatality. The overcoming prevalence of resistant gram-negative and positive bacteria (e.g., methicillin-resistant Staphylococcus aureus, penicillin and ceftriaxone-resistant Streptococcus pneumoniae, extended-spectrum β-lactamases and carbapenemases producing Enterobacteriaceae) has made the most of the first-line agents ineffective for treating lower respiratory tract infections. A broad-spectrum of activity, favourable pulmonary penetration, harmlessness and avoiding in some cases a combination therapy, characterise new cephalosporins such as ceftolozane/tazobactam, ceftobiprole, ceftazidime/avibactam and ceftaroline. We aimed to summarise the role and place in therapy of new cephalosporins in community- and hospital-acquired pneumonia within the setting of internal medicine wards. The "universal pneumonia antibiotic strategy" is no longer acceptable for treating lung infections. Antimicrobial therapy should be individualized considering local antim...
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Tags: J Thorac Dis Source Type: research

Related Links:

Staphylococcus aureus is a leading cause for clinical infections and food intoxications, causing over 100,000 yearly cases of bacteremia in the United States and 434 food-borne outbreaks in the European Union. Approximately 30% of the population permanently carry S. aureus asymptomatically in their nasal cavity. The risk of infection and transmission to food items or the environment is higher in individuals that are nasally colonized. In addition, S. aureus can acquire various antimicrobial resistances leading to therapeutic failure, additional medical costs, and fatalities. Methicillin-resistant S. aureus (MRSA) cause a c...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Yamuna Devi Bakthavatchalam, Shoma Vinay Rao, Barney Isaac, Abi Manesh, Senthur Nambi, Subramanian Swaminathan, Vasanth Nagvekar, Vivek Nangia, Peter Victor John, Balaji VeeraraghavanIndian Journal of Medical Microbiology 2019 37(4):478-487Staphylococcus aureus is of significant clinical concern in both community- and hospital-onset infections. The key to the success of S. aureus as a pathogen is its ability to swiftly develop antimicrobial resistance. Methicillin-resistant S. aureus (MRSA) is not only resistant to nearly all beta-lactams but also demonstrates resistance to several classes of antibiotics. A high prevalence...
Source: Indian Journal of Medical Microbiology - Category: Microbiology Authors: Source Type: research
ConclusionsHigh levels of resistance to second-line antimicrobials threatens the treatment of nosocomial respiratory infections due to methicillin-resistantS. aureus with decreased susceptibility to linezolid and vancomycin. The wide genotypic diversity found reinforces the central role of ICU infection control in preventing nosocomial transmission.
Source: Antimicrobial Resistance and Infection Control - Category: Infectious Diseases Source Type: research
Authors: Panchal G, Pandit R, Trailokya A, Sharma A Abstract Antibiotic resistance is one of the biggest menace to global health. Deaths from Drug-resistant infections is set to escalate exponentially. Pipeline for new antibacterials is almost empty. The World Health Organization has reinforced its warning that to tackle growing threat of antimicrobial resistance, development of a new antibiotics is seriously lacking. Arbekacin is a novel aminoglycoside primarily used in the treatment of infections caused by resistant Staphylococcus Aureus i.e. Methicillin Resistant Staphylococcus Aureus (MRSA). Besides MRSA it als...
Source: Journal of the Association of Physicians of India - Category: General Medicine Tags: J Assoc Physicians India Source Type: research
ConclusionSevere community-acquired pneumonia was treated with macrolides in combination with vancomycin or linezolid if methicillin-resistant S. aureus was suspected. This was appropriate, in view of its causative agents and their susceptibility pattern. Hospital and ventilator-associated pneumonia caused by resistant Gram-negative organisms might have better outcomes by adding tigecycline or colistin in combination with fluoroquinolones. Owing to the widespread resistance of many Gram-negative bacteria, it is recommended that the antibiotic stewardship program be frequently updated.
Source: Journal of Global Antimicrobial Resistance - Category: Infectious Diseases Source Type: research
CONCLUSIONS: DM patients with poor glucose control are more susceptible to MRSA infection. They suffer from higher antimicrobial resistance, a higher co-infection rate, and much severer pneumonia than non-DM. MRSA itself is an independent risk factor for mortality in all patients. PMID: 31205100 [PubMed - in process]
Source: Chinese Medical Journal - Category: General Medicine Authors: Tags: Chin Med J (Engl) Source Type: research
Conclusion: PVL expression is high among clinical S. aureus strains among Gambian patients. Reporting of PVL-SA clinical infections is necessary to enable the monitoring of the clinical impact of these strains in the population and guide prevention of the spread of virulent PVL-positive CA-MRSA strains.
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
Conclusions: We present the most detailed genomic analysis of MRSA isolated in Sri Lanka to date. The analysis identified a PVL-positive ST5-MRSA-IVc that is prevalent among MRSA causing clinical infections in Sri Lanka. Furthermore, this clone was also found among isolates from the United Kingdom and Australia. Introduction Worldwide, Staphylococcus aureus is the primary causative agent of community-acquired skin and soft tissue infections (SSTI) and is an important cause of hospital-associated invasive infections including bacteremia, pneumonia and endocarditis (Bell et al., 2002; David and Daum, 2010). Panton-Va...
Source: Frontiers in cellular and infection microbiology - Category: Microbiology Source Type: research
Conclusion The results of our study demonstrate that robenidine is not suitable as a sole antimicrobial agent for the treatment of Gram-negative pathogen infections due to the lack of activity against the majority of Gram-negative isolates except for A. baumannii and A. calcoaceticus. However, we demonstrated in vitro efficacy against all selected Gram-negative organisms when robenidine was tested in combination with EDTA or PMBN, including against multidrug-resistant strains. Therefore, robenidine may be an appropriate candidate as a component of a combination preparation for the treatment of otitis externa in dogs. This...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
This study identified prophages as mediators of bacterial virulence in a model of infectious endocarditis, probably through promotion of interaction with extracellular matrix components. Further studies are needed to identify mechanisms leading to promotion of intrinsic virulence. Introduction Challenges related to Staphylococcus aureus infections in the human and veterinary clinics mobilized important human and technical resources. S. aureus can colonize 20–30% of the general population asymptomatically but is also capable of causing a wide spectrum of diseases ranging from benign infections, to particularly...
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
More News: Antibiotic Therapy | Antimicrobial Resistance | Ceftriaxone | Epidemiology | Healthcare Costs | Hospitals | Internal Medicine | MRSA | Penicillin | Pneumonia | Respiratory Medicine | Rocephin | Staphylococcus Aureus